We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 13, 2022

Clinical Outcomes in Patients With CLL With and Without del(17p) Receiving First-Line Ibrutinib



Additional Info

Disclosure statements are available on the authors' profiles:

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Haematologica 2022 Apr 21;[EPub Ahead of Print], AR Mato, B Tang, S Azmi, K Yang, X Zhang, JC Stern, E Hedrick, J Huang, JP Sharman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading